Open AccessNeurologic uses of botulinum neurotoxin type A
Author(s) -
John P. Ney
Publication year - 2008
Publication title -
neuropsychiatric disease and treatment
Language(s) - English
Resource type - Journals
eISSN - 1178-2021
pISSN - 1176-6328
DOI - 10.2147/ndt.s1612
Subject(s) - medicine , botulinum neurotoxin , blepharospasm , spasticity , neurochemical , movement disorders , physical medicine and rehabilitation , clinical trial , neuroscience , intensive care medicine , bioinformatics , botulinum toxin , pathology , surgery , biochemistry , chemistry , disease , toxin , biology
This article reviews the current and most neurologic uses of botulinum neurotoxin type A (BoNT-A), beginning with relevant historical data, neurochemical mechanism at the neuromuscular junction. Current commercial preparations of BoNT-A are reviewed, as are immunologic issues relating to secondary failure of BoNT-A therapy. Clinical uses are summarized with an emphasis on controlled clinical trials (as appropriate), including facial movement disorders, focal neck and limb dystonias, spasticity, hypersecretory syndromes, and pain.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom